We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Thanks, but no thanks

9 Jun 2006 By Robert Cyran

The drugs group lost more than $4bn of value in a week when bids for the consumer arm came in much higher than expected. This may reflect concerns it will get hit with a big tax bill and then let the proceeds gather moss in its flabby balance sheet.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)